CDMO News
ITM Signs Supply Deal to Provide Radiopharm with Lutetium-177 for Cancer Therapies
ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company, has signed a supply agreement with Radiopharm Theranostics to provide its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu). The agreement will support Radiopharm’s ongoing and future development of targeted radiopharmaceutical therapies for solid tumours.
23 May 2025